Last reviewed · How we verify
NCT05145101: Pneumo-CLL
Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia
trial testing Prevnar13 in Pneumococcal Infections in 150 participants. Status unknown.
31 March 2022
Quick facts
| Lead sponsor | Hannah Garcia Garrido |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 7 May 2020 |
| Primary completion | 31 March 2022 |
| Estimated completion | 31 March 2022 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Prevnar13 — full drug profile →
Conditions studied
- Pneumococcal Infections — all drugs for Pneumococcal Infections →
- Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
- Vaccine-Preventable Diseases — all drugs for Vaccine-Preventable Diseases →
- Invasive Pneumococcal Disease, Recurrent Isolated — all drugs for Invasive Pneumococcal Disease, Recurrent Isolated →
Sponsor
Hannah Garcia Garrido
Who can join
18 and older, any sex, with Pneumococcal Infections or Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study the antibody response after vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23) in adults with chronic lymphocytic leukemia will be investigated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05145101
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Prevnar13
Trials testing the same drug.
- NCT04978038 — Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs · Phase 4 · unknown
- NCT03376477 — Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission · Phase 2 · terminated
- NCT03621670 — Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomita · Phase 3 · completed
- NCT03549208 — A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults · Phase 1 · unknown
- NCT03467984 — A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants · Phase 2 · completed
Other recruiting trials for Pneumococcal Infections
Currently open trials in the same condition.
- NCT06822907 — Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults · Phase 4 · recruiting
- NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
- NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
- NCT06608199 — A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 · Phase 3 · recruiting
- NCT04945681 — Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05145101 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hannah Garcia Garrido
- Last refreshed: 20 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05145101.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing